logo
Share SHARE
FONT-SIZE Plus   Neg

4SC's Anti-Cancer Drug Resminostat Achieves Median Overall Survival Of 8 Months

4SC AG (FSCGF.PK) announced the publication of convincing overall survival data from a Phase II study with its lead anti-cancer drug resminostat applied as a novel combination therapy approach with sorafenib in second-line advanced liver cancer at the 2012 annual meeting of the International Liver Cancer Association in Berlin, Germany, on September 16, 2012. The international, open-label, two-arm SHELTER trial enrolled patients with advanced liver cancer who had demonstrated proven radiological tumor progression under first-line therapy with the cancer drug sorafenib.

The study investigated safety and efficacy of resminostat as a monotherapy and in combination with sorafenib in this patient group with currently no approved treatment option.

Final median overall survival of 8.0 months was determined in the resminostat/sorafenib combination 'intend-to-treat' population, i.e. all study patients who were treated with the combination of 600 mg resminostat total daily dose and 400 mg sorafenib TDD. According to the company, the data for the resminostat/sorafenib combination therapy showed a progression-free survival rate after 12 weeks of treatment of 70.0% and a median PFS of 4.7 months.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Kik Interactive Inc., the parent of chat app Kik, said it will launch a new cryptocurrency or token called Kin for use in everyday digital services, such as chat, social media and payments. Kik said it has decided to propose a new ecosystem of digital services that will be truly open and decentralized, and will start with a new cryptocurrency. Several companies have pulled advertisements from Sean Hannity's Fox News show after he continued to promote a conspiracy theory about Democratic National Committee staffer Seth Rich's death. Hannity has come under fire for spreading a conspiracy theory linking Rich's killing to Wikileaks. Best Buy Co., Inc. reported lower profit in its first quarter on the absence of last year's CRT settlement proceeds. However, earnings per share topped market estimates significantly with higher comparable sales. Looking ahead, for the second quarter, the company projects higher comparable sales, and also lifted fiscal 2018 forecast for higher growth.In pre-market, shares were gaining 11.9 percent
comments powered by Disqus
Follow RTT